Pomerantz Law Firm Investigates Theravance Biopharma for Potential Securities Fraud
Pomerantz LLP is investigating Theravance Biopharma (NASDAQ: TBPH) for potential securities fraud following the announcement of failed Phase 3 trial results for ampreloxetine, which led to a 26.33% drop in the company's stock price. The firm is seeking investors to join a class action lawsuit.
Tickers: $TBPH
Topics: clinical trial results investor rights securities fraud stock price drop